Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
NCT04655092
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
67
Enrollment
INDUSTRY
Sponsor class
Conditions
Polycythemia Vera (PV)
Interventions
BIOLOGICAL:
P1101 (Ropeginterferon alfa-2b)
Sponsor
PharmaEssentia Japan K.K.